CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.   Editas ...

Editas Medicine, Inc. - Barclays 26th Annual Global Healthcare Conference Summary Company Overview - **Company**: Editas Medicine, Inc. (NASDAQ:EDIT) - **Industry**: Biotechnology, specifically focused on genome editing using CRISPR technology - **Key Participants**: - Gilmore O'Neil - Chief Executive Officer - Erick Lucera - Chief Financial Officer Core Strategy 1. **Lead Clinical Asset**: - Reni-cel, a CRISPR edited Cas12a cell-based therapy targeting sickle cell disease and thalassemia, is being advanced through clinical trials [2][3]. 2. **Discovery Focus**: - Emphasis on in vivo CRISPR editing to unlock the potential of CRISPR technology for durable therapies [2]. 3. **Business Development**: - Aggressive strategy to evaluate and acquire technologies that enhance the in vivo platform and pipeline, as well as out-licensing exclusive IP for Cas9 and Cas12 in human therapeutics [3]. Clinical Development and Regulatory Path - **Reni-cel Development**: - Fast follower with potential best-in-class status, focusing on upregulating fetal hemoglobin and correcting anemia in sickle cell disease [5]. - **Regulatory Designation**: - Received RMAT designation from the FDA in November, indicating recognition of unmet medical needs [5]. - **Clinical Study Updates**: - 40 patients enrolled in the RUBY study, with 18 patients dosed, showing significant progress compared to previous quarters [11][26]. - **Regulatory Benchmarking**: - Using CASGEVY's approval as a benchmark for regulatory submissions, aiming for a similar patient cohort and follow-up timeline [6][8]. Data and Metrics - **Upcoming Data Releases**: - Mid-year updates expected to include hematological parameters, safety, and engraftment data from at least 20 patients [18]. - **Clinical Outcomes**: - Focus on clinical vaso-occlusive events and hematological parameters, including fetal hemoglobin levels [19]. Competitive Landscape - **Market Positioning**: - Positive sentiment from KOLs regarding the clinical meaningfulness of Reni-cel, with a focus on achieving normal physiological hemoglobin levels [24][25]. - **Enrollment Impact**: - No negative impact on patient enrollment despite competitive pressures; increased dosing from 11 to 18 patients in recent quarters [26]. In Vivo Pipeline - **Future Developments**: - Plans to disclose updates on in vivo programs targeting hematopoietic stem cells and other tissues in the second half of the year [33]. - **Target Selection**: - Commitment to developing targets that provide clinically meaningful benefits through genome editing, avoiding areas where other modalities can compete [36]. Business Development and Financials - **Licensing Strategy**: - Two-pronged approach for business development: traditional licensing of Cas9 and Cas12 technologies and out-licensing of in vivo targets not pursued internally [38]. - **Cash Position**: - Ended the year with $427 million in cash, expected to sustain operations into 2026 [40]. Conclusion - Editas Medicine is advancing its CRISPR-based therapies with a strong clinical pipeline and strategic focus on in vivo applications, while maintaining a solid financial position to support its growth and development initiatives.

Editas Medicine, Inc. (NASDAQ:EDIT) Leerink Partners Global Biopharma Conference March 12, 2024 10:40 AM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - Conference Call Participants Mani Foroohar - Leerink Mani Foroohar Good morning, everyone. Welcome back to the 2024 Global Biopharma Conference, Inaugural Miami Conference. So welcome everybody down. I am Mani Foroohar, Senior Analyst Genetic Medicines. And I'm very fortunate to be hosting the team from Editas Medicine. How are you doing? Gilm ...

With Citigroup analyst Samantha Semenkow calling on Feb. 29 for shares of Editas Medicine (EDIT -0.66%) to rise from their current price near $10 to reach $16 -- an increase of 45% over her prior estimate -- there's a clear consensus about the stock forming on Wall Street. Based on Semenkow's price target, which is effectively the same as the consensus average price target across analysts following the stock, Editas Medicine is looking at a 70% bump.It could happen. Here's why.This company just got a huge b ...

Editas Medicine, Inc. Conference Call Summary Company Overview - **Company**: Editas Medicine, Inc. (NASDAQ:EDIT) - **Date**: March 4, 2024 - **Participants**: Gilmore O'Neill (CEO), Erick Lucera (CFO), Phil Nadeau (TD Cowen Analyst) Key Points Company Strategy and Strengths - Editas has outlined a new strategy with three pillars: 1. Advancing lead asset **reni-cel** towards BLA and commercialization 2. Focusing on in vivo pipeline efforts, with a preclinical proof-of-concept expected this year 3. Enhancing business development (BD) efforts, particularly through out-licensing IP for non-dilutive capital formation [2][5] - The company possesses strong scientific capabilities in computational biology and genetics, along with robust chemistry for guide RNA and a solid CMC organization [3] Challenges - A significant challenge is helping the world recognize the transformative value of gene editing, particularly in delivering durable treatments that alleviate patient burdens and improve compliance [4] Reni-cel Development - Reni-cel aims to upregulate fetal hemoglobin to reduce vaso-occlusive events in sickle cell disease. The approach uses the **ASCas12a CRISPR enzyme**, which is noted for its high fidelity and efficiency compared to Cas9 [7] - Clinical data shows that patients have achieved fetal hemoglobin levels exceeding 40%, which is expected to eliminate vaso-occlusive events [12] Clinical Trials and Updates - The **RUBY study** has dosed 18 patients, with enrollment increasing from 27 to 40. The study is designed to monitor vaso-occlusive events and hematologic parameters [18][19] - The FDA has agreed to transition the RUBY Phase 1,2 study to a Phase 1,2,3 study, allowing the use of all collected data for future filings [25][26] Market Size and Differentiation - The market for severe sickle cell disease is estimated at 25,000 to 30,000 patients in the U.S., with adolescents representing a fraction of this population [35] - Editas aims to differentiate reni-cel through clinical outcomes, including correction of anemia and end organ function [20][21] Beta Thalassemia Program - Editas has dosed 7 patients in its beta thalassemia program, targeting transfusion-dependent patients. Updates are expected mid-year and at the end of the year [41][42] Manufacturing and Capacity - Editas has partnered with Azure to lease clean rooms for commercial capacity, emphasizing a capital-efficient approach to manufacturing [46][48] Financial Position - As of year-end, Editas reported $427 million in cash, expected to last into 2026. The company also plans to monetize its IP portfolio for additional non-dilutive capital [64] Intellectual Property and Business Development - Editas is open to bespoke licensing agreements and in-licensing complementary technologies to enhance its pipeline [55][62] Additional Insights - The leadership team is focused on under-promising and over-delivering as the company transitions from a development platform to a commercial therapeutics company [31] - The company is actively monitoring clinical and physiological parameters to support differentiation claims in its therapies [22][23]

Although equities have performed pretty well in the past three years, many somewhat speculative and unprofitable stocks have struggled as investors have turned their attention away from such corporations. That's the case with Editas Medicine (EDIT -2.47%), a clinical-stage gene editing-focused biotech company.However, many analysts on Wall Street have high hopes for the stock. Editas Medicine's average price target of $15.64 implies an upside of about 55% over its stock price of $10.06 (as of writing). Can ...

Shares of Editas Medicine (EDIT 4.67%) charged sharply higher this week, soaring as much as 41.6%, according to data from S&P Global Market Intelligence. By the time the market closed on Friday, the stock was still up 34.8%.The catalyst that vaulted the gene editing specialist higher was the company's quarterly report, which included a surprise announcement.Alignment with the FDAOn Wednesday, Editas Medicine released its fourth-quarter results, which were better than investors had hoped. The company generat ...

Editas Medicine, Inc. (EDIT) incurred a loss of 23 cents per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 52 cents. The company had reported a loss of 88 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $60 million in the reported quarter, up significantly from $6.5 million reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate o ...

Financial Data and Key Metrics Changes - The company reported cash, cash equivalents, and marketable securities of $427 million as of December 31, 2023, down from $446 million as of September 30, 2023 [46] - Revenue for the fourth quarter of 2023 was $60 million, primarily from a license agreement with Vertex [47] - R&D expenses increased by $18 million to $70 million compared to the fourth quarter of 2022, reflecting additional sub-license expenses [65] - G&A expenses for the fourth quarter of 2023 were $14 million, down from $18 million in the same quarter of 2022 [78] Business Line Data and Key Metrics Changes - The company has enrolled 40 sickle cell and 9 beta thalassemia patients in the RUBY and EdiTHAL studies, with 18 RUBY patients and 7 EdiTHAL patients dosed [27][41] - The RUBY trial is now considered a Phase 1, 2, 3 study for BLA submission, with alignment on study design and endpoints with the FDA [42][36] Market Data and Key Metrics Changes - The company is focused on the gene editing market, particularly in hemoglobinopathies, and has engaged with the FDA regarding the RUBY trial [34][55] - The competitive landscape includes a recently approved gene editing treatment for sickle cell disease, which the company is monitoring closely [104] Company Strategy and Development Direction - The company aims to drive reni-cel towards BLA and commercialization, strengthen its discovery organization, and increase business development activities [34] - The company has decided not to pursue internal development of a milder conditioning regimen, focusing instead on in vivo HSE medicines [55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for reni-cel to provide a competitive edge in the market [62] - The company plans to provide clinical updates from the RUBY and EdiTHAL trials in mid-2024 and by year-end 2024 [39] Other Important Information - The company has strengthened its senior leadership team with experienced professionals in drug development and commercialization [34] - The company has activated over 20 sites for the RUBY trial, with ongoing patient recruitment and dosing [100] Q&A Session Summary Question: Can you elaborate on the hemolysis markers being tracked? - The company tracks multiple hemolysis markers including reticulocyte, LDH, and bilirubin, and uses various instruments to measure patient-reported outcomes related to quality of life [70] Question: Can you share insights into your FDA conversations regarding the RUBY trial? - The company has aligned with the FDA on the RUBY trial as a Phase 1, 2, 3 study, including endpoint, sample size, and study design [72][74] Question: How does the Phase 1, 2, 3 designation impact the BLA path? - The designation allows for a seamless transition to support the BLA, utilizing all patient data from the study [102][88] Question: What are the latest thoughts on how reni-cel fits in the market? - The company sees robust market development and initial interest from stakeholders, with ongoing engagement in clinical studies [105] Question: Can you provide an update on the CRISPR-Cas9 appeal case? - The Court of Appeals has yet to schedule an oral hearing, but it is expected to occur sometime in 2024 [96] Question: What is the status of the adolescent cohort in the RUBY study? - The adolescent cohort has been initiated, with high interest and demand from patients [59] Question: How is the company addressing the patient experience with reni-cel? - The company is pleased with the number of apheresis cycles required and reports that all patients have achieved engraftment within 30 days [167]

Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.77%. A quarter ago, it was expected that this genome editing company would post a loss of $0.64 per share when it actually produced a loss of $0.55, delivering a surprise of 14.06%.Over the last four quarters, the compa ...